fashion -WSS

fashion

author：comprehensive 2025-10-01 21:35:48 - browse：76

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Lilly's Alzheimer's drug donanemab backed by FDA advisers

leisure time

WSS

Deposition: Sackler embraced plan to conceal OxyContin’s strength

'Little Tech' descents on D.C., wanting a say in how AI is regulated

FDA approves Moderna’s RSV vaccine, its second licensed product

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Data don't support strong claims for Covid

Stephen Quake on the Chan Zuckerberg quest to conquer disease

entertainment

fashion

entertainment

Moonlake's readout produced a cash windfall. Risks remain

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Hepatitis C has a cure — but many Americans still lack access to it

ALS patient reclaims some autonomy thanks to wearable 'robot'

Duchenne breakthrough therapy leaves behind pioneering families

Sutter Health’s antitrust win overturned by appeals court

Hepatitis C has a cure — but many Americans still lack access to it

STAT wants to know your pick for a great summer read or listen

Duchenne breakthrough therapy leaves behind pioneering families

My daughter's legacy lives on through her writing, phage therapy

entertainment

'Little Tech' descents on D.C., wanting a say in how AI is regulated

My daughter's legacy lives on through her writing, phage therapy

Moderna says combo Covid

Congress needs to close a vaccine

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

FDA approves Moderna’s RSV vaccine, its second licensed product

hotspot

leisure time

Wikipedia

knowledge